循環細胞フリーKRAS G12Cの早期変化がKRAS変異非小細胞肺癌患者におけるアダグラスビブへの反応を予測することを示す補足図3

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Supplemental Figure 3 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
2. 2Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
3. 3Supplemental Figure 4 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
4. 4Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024
5. 5Supplemental Figure 1 from Early changes in circulating cell free <i>KRAS</i> G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients2024